240 related articles for article (PubMed ID: 35407421)
1. Therapeutic Drug Monitoring in Perianal Fistulizing Crohn's Disease.
Zulqarnain M; Deepak P; Yarur AJ
J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407421
[TBL] [Abstract][Full Text] [Related]
2. Association of Neutrophil Extracellular Traps with Fistula Healing in Patients with Complex Perianal Fistulizing Crohn's Disease.
Cao D; Qian K; Zhao Y; Hong J; Chen H; Wang X; Yang N; Zhang C; Cao J; Jia K; Wu G; Zhu M; Shen J; Zhang Y; Cui Z; Wang Z
J Crohns Colitis; 2023 Apr; 17(4):580-592. PubMed ID: 36322703
[TBL] [Abstract][Full Text] [Related]
3. Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn's disease: a narrative review.
Miranda EF; Nones RB; Kotze PG
Intest Res; 2021 Jul; 19(3):255-264. PubMed ID: 33147899
[TBL] [Abstract][Full Text] [Related]
4. Higher Adalimumab Concentration is Associated with Complete Fistula Healing in Patients with Perianal Fistulizing Crohn's Disease.
Papamichael K; Centritto A; Guillo L; Hier J; Sherman Z; Cheifetz AS;
Clin Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38692557
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
Tonelli F; Giudici F; Asteria CR
Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
[TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and prognosis of children with perianal fistulizing Crohn's disease].
Fang YH; Luo YY; Zhang RF; Cheng Q; Chen J
Zhongguo Dang Dai Er Ke Za Zhi; 2024 Jan; 26(1):42-47. PubMed ID: 38269458
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis.
Ayoub F; Odenwald M; Micic D; Dalal SR; Pekow J; Cohen RD; Rubin DT; Sakuraba A
Intest Res; 2022 Apr; 20(2):240-250. PubMed ID: 35124951
[TBL] [Abstract][Full Text] [Related]
8. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn's disease.
Plevris N; Jenkinson PW; Arnott ID; Jones GR; Lees CW
Eur J Gastroenterol Hepatol; 2020 Jan; 32(1):32-37. PubMed ID: 31567638
[TBL] [Abstract][Full Text] [Related]
9. Approach to medical therapy in perianal Crohn's disease.
Vasudevan A; Bruining DH; Loftus EV; Faubion W; Ehman EC; Raffals L
World J Gastroenterol; 2021 Jul; 27(25):3693-3704. PubMed ID: 34321838
[TBL] [Abstract][Full Text] [Related]
10. Management of Perianal Fistulizing Crohn's Disease.
Singh A; Midha V; Kochhar GS; Shen B; Sood A
Inflamm Bowel Dis; 2023 Sep; ():. PubMed ID: 37672347
[TBL] [Abstract][Full Text] [Related]
11. Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy.
Papamichael K; Cheifetz AS
World J Gastroenterol; 2017 Sep; 23(34):6197-6200. PubMed ID: 28974885
[TBL] [Abstract][Full Text] [Related]
12. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Medical Therapies for Fistulizing Crohn's Disease: Systematic Review and Meta-analysis.
Lee MJ; Parker CE; Taylor SR; Guizzetti L; Feagan BG; Lobo AJ; Jairath V
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1879-1892. PubMed ID: 29374617
[TBL] [Abstract][Full Text] [Related]
14. Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients.
Strik AS; Löwenberg M; Buskens CJ; B Gecse K; I Ponsioen C; Bemelman WA; D'Haens GR
Scand J Gastroenterol; 2019 Apr; 54(4):453-458. PubMed ID: 31032686
[No Abstract] [Full Text] [Related]
15. Evaluating the effectiveness of infliximab on perianal fistulizing Crohn's disease by magnetic resonance imaging.
Yan X; Zhu M; Feng Q; Yan Y; Peng J; Xu X; Xu A; Ran Z
Gastroenterol Rep (Oxf); 2019 Feb; 7(1):50-56. PubMed ID: 30792866
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF and fistulizing perianal Crohn's disease: use in clinical practice.
Bourikas LA; Koutroubakis IE
Curr Drug Targets; 2010 Feb; 11(2):187-97. PubMed ID: 19916954
[TBL] [Abstract][Full Text] [Related]
17. Strategies to Optimize Anti-tumor Necrosis Factor Therapy for Perianal Fistulizing Crohn's Disease: A Systematic Review.
Tandon P; Rhee GG; Schwartz D; McCurdy JD
Dig Dis Sci; 2019 Nov; 64(11):3066-3077. PubMed ID: 31030304
[TBL] [Abstract][Full Text] [Related]
18. Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn's disease.
Newman KL; Johnson LA; Stidham RW; Higgins PDR
Therap Adv Gastroenterol; 2023; 16():17562848221148254. PubMed ID: 36895282
[TBL] [Abstract][Full Text] [Related]
19. Remicade does not abolish the need for surgery in fistulizing Crohn's disease.
Poritz LS; Rowe WA; Koltun WA
Dis Colon Rectum; 2002 Jun; 45(6):771-5. PubMed ID: 12072629
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
